GR1603458162
final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1 18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..
#035 -2 0 1 6
www . v i r u s . c o m . g rI S S N : 2 2 4 1 - 0 9 6 1
pi
pi
4 Clinical Research ConferenceThink Tank
001 EX.indd 1 3/3/2016 7:50:57 pi
/ #0
35
/
-
2
01
6ISSN
: 224
1-09
61
00 ANAPTYGMA EXOFYLOU.indd 1 3/3/2016 7:51:39 pi
/ #03
7 /
-
2016
final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1 18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..
#035 -2 0 1 6
www . v i r u s . c o m . g rI S S N : 2 2 4 1 - 0 9 6 1
pi
pi
4 Clinical Research ConferenceThink Tank
001 EX.indd 1 3/3/2016 7:50:57 pi
/ #0
35
/
-
2
01
6ISSN
: 224
1-09
61
00 ANAPTYGMA EXOFYLOU.indd 1 3/3/2016 7:51:39 pi
#037- 2 0 1 6
Jean-Michel Malbrancq
C
PFI
-02-
FEB
16
Pfizer, - , 1849 .
, .
C
M
Y
CM
MY
CY
CMY
K
AbbVie_bestworkplaces2016TEL2_21x28.pdf 1 4/7/16 2:00 PM
1GR-MEN-ADV-03/2016
Menarini_KTX_21x28_GREEK_03_16.pdf 1 3/3/2016 2:32:51
2 / - 2016
6.
8. Jean-Michel Malbrancq
16.
24.
29. : C
30.
34. I.H. Mameletzis
40. Infographic
42.
#037- 2016 10
[email protected] - : [email protected]
08
24
34
3 & : -A [email protected]
DIGITAL MARKETING: [email protected]
: Shutterstock
- : Pressious ....
:
29, 174 56
48.
C
52.
C
56.
60.
68.
71. Virus
76. VRS
78. 30
,,,
T: 210 9984950, : 210 9984953 E: [email protected] www.virus.com.gr www.phb.com.gr
www.ethosmedia.eu www.ethosevents.eu www.alivemag.gr www.hrima.gr www.insuranceworld.gr www.asfalizomai.com
ISSN: 2241-0961
56
16
42
E D I T R I A L
4 / - 2016
,
,
...
editorial
...
. -
7,5 . .
. ;
: 7,5 ., 5,3
. -
2,2 . ,
-
5 . !
,
(, -
)
3 . !
700 .
5 ,
.
5 ...
. , ,
...
200 -
.
. ,
600 .
!
-
. -
, ,
-
.
,
.
, . -
, ,
, -
.
.I .
.
Gilead Sciences , . .
Gilead ( HIV/AIDS ), ( ) / .
, 42% . .
998/
GR
/12-
01//1
003(
2)
5 .I .
.
Gilead Sciences , . .
Gilead ( HIV/AIDS ), ( ) / .
, 42% . .
998/
GR
/12-
01//1
003(
2)
6 / - 2016
- . - , site -, - . , , , , . - , . , , - , , .
*
, - . - - , - -, - . - - . , , . . , , . , () . - , . - .
7*
- , - - . , , - , - , - - . - - (). , , , - . PhB , - , . , - , - . , PhB, -
2007 - - . - 10 , . - . - , , . - PhB . , -, , -. - , . , , .
, - . - , PhB - - , . - - - , . , -, PhB. , , , , . , - , -
8
/ - 20168
/ - 2016
9 - - - Jean-Michel Malbrancq, GE Healthcare . . : - ... - . ,
. - - -, . GE, , - -: . -, , - (, PET), - ...
H PhB GE Healthcare .
:
* GE Healthcare
Jean-Michel Malbrancq*
9
A MD, MSc, PhD, & , Jean-Michel Malbrancq, & CEO GE Healthcare Europe
10
/ - 2016
_ , , - , . . ; ;
_ - . 15 , GE 7 . - PET-CT - , - - . -, , , -, .
_ PET-CT Discovery IQ. ;
_ 70%, -
70% - . - , . Discovery IQ PET-CT - . PET CT, - -. - . - - - .
_ Jean-Michel, GE 30 ! PET-CT. ;
_ 30 , -! GE , - - PET-CY, -, . PET-CT - .
, ,
,
11
PET-CT 2001. - : , , - - - . - PET-CT - , - - , - . GE - - PET-CT PET-MR.
_ , - PET-MR. ;
_ PET-CT, PET-MR - , -. , . , PET-CT - 95% . PET-MR, - - - . - -, , - .
_ - healthymagination. -; GE;
_ Healthymagination : - - , , , ,
- . - , - . - . Vscan GE : , - - - . , , - - - (, ..). , - , .
_ - - . . , - . GE;
_ , - . - - , - . . , - . - - : - , . ,
12
/ - 2016
- . GE - -. , 1 . . . , - . , - - . - - , .
_ , - ;
_ , PET-CT PET-MR, - , . , , - , - (, PET), . GE Health Cloud, , -, , , . -
.
_ GE - -, - , . , - -, ;
_ - : -, - . . , - , . , - , - . , , . GE - , - - .
Jean-Michel Malbrancq 13 1956. - Compigne 1980. 1983 1987 Thomson CGR, -, GE 1987, . 1987 2005, GE ,
Jean-Michel - , - , - - (CT) 2001. 2005, Milwaukee . , - ,
. 2009, Jean-Michel GE Healthcare , 2011 - - . , 20 , . - .
Who is who
Healthymagination
13
GE Medical Systems GE Healthcare Technologies, - GE Medical Systems , , , -. , - - . - :
- (MRI)
- (CT)
--(Vascular-Cardiovascular)
(Nuclear Medicine)
-- (PET-CT)
- - (X-RAY)
(Mammography)
(Ultrasound)
(Bone Mineral Densitometers)
- (Monitoring)
- (PACS, ..)
, GE Medical Systems GE Healthcare Technologies - - , , - , :
-
.
.
, - .
- - internet - iLink, InSite.
- .
- .
, , , nSiteTM GE Medical Systems GE Healthcare Technologies (), USA (Milwaukee) (Tokyo), - - 45 . 2004, GE Medical Systems - Amersham Health, , , GE Healthcare, - - , - - , , - - .
H GE Healthcare
PET-CT
14
/ - 2016
, 15 -. , - GE Healthcare. - , PET/CT , - 5 . , GE Healthcare - PET/CT Discovery IQ , - - MR Optima 450W with GEM Suite GE Healthcare, 1.5 Tesla. , - -
, . , -. -, PET/CT
.
, 61% clawback rebate, , -, 18 . - 2007-2011. - , , - , , , . - -, , . , 10 5 ! , - (PET/CT) - (CT) - - (), - . - - . - -, 18 . , - - MR Optima 450W with MR Optima 450WGEM Suite GE Healthcare, 1.5 Tesla. - , , -
, PET-CT
PET-MR,
15
, . GE Healthcare , Jean Michel Malbrancq. - , -, , , , - - 70% 2 - Malbrancq. , - - . , -. , - PET/CT, - . GE Healthcare 2005, 2009 - GE. - - - .
, - 5 1.000 2.200 .. , - -. - . , , ( . ), . , 180 60-90% .
15
16
/ - 2016
! , , - (). , - - - . -, , . PhB
, , . - PhB . - , , - . , 35 , - , - - . -
PhB , , .
.
17
18
/ - 2016
. , - - . , , . - , , . 350-400 . . - , - , - . , - , . , -, . - :
- - . - ,
- - . , - , - . . - - , - . , - -. - :
(-, , -).
- - , - , , , - .
- , - , - .
- (), - (, -, ..), - . , ,
PhB
.
19
- - . - , - . - - , , . - - , . (-) , - ( ), .
- - - . - . - , . - . - , : - . - - , -, , . - , . - - . -
, - , - . (peer to peer) - . 8 .. 8 .. , - -, , , - . , - , , - 24 - , . - , -, :
- -
(, , - , , )
-
-
(,
)
-
. -
( , ).
-, , , .
350-400 .
20
/ - 2016
, -, - , .
- (- , , -, ).
- - .
, - , - - - .
- .
- - .
- -.
, - , , .
- - -, .
- - , , , ,
- .
- , - - .
- .
, , - . , - -. - . . -, :
-
-
/-
, , , -
21
.
- - , ( , -, ..).
, -. - , , - - . - , - , - .
- - gatekeepers, - , - , - .
, - - , , , - , - , - .
-
, - . - . - , - , - - .
() - (-, , ), - (, , , ).
, - , - - , - .
- , - - .
, , - , , - - .
12 10.000
22
/ - 2016
:
-- - . , - - - , , - . , -. - . - , . - -
, - . , - - .
, 2.000-2.500 - , 1.000 , , 12 (4 , 1 - , 2 - 2 , 1 , 2 - ) 10.000 . - 1/4 - 20.000 . -, , - . -
,
2016 2017 2018 2019 2020
500.000 1.250.000 2.250.000 3.250.000 4.250.000
% 8,285 . / 6% 15,2% 27,2% 39,2% 51,3%
% , 4,5% 11,3% 20,4% 29,4% 38,5%
27.314.899 1.229.000 3.091.000 5.572.000 8.031.000 10.401.000
, ,
420.000-
480.000
23
- . :
. (- ).
. - , - .
- 4 . - (, - , , - ..).
(2016-2017) / 40-50 - ( 5% )
(2018-2020) -- .: 5 ( 25% )
(2021-2027): - (80% )
,
, - 420.000-480.000 . , , 350-400 . , - 0,2-0,3% 3-4% - . - ( , - ..), - . - , -, , - 60-70% , - . - - . , 27,3 . - 2014 : 11,9 . 9.189 -, 6,1 . 2.306 - 9,3 . 5.384 -. , - , -, . () - (1.299 ) (2.644 ).
2016 2017 2018 2019 2020
/ ( : 1.724 .//) 712 1.793 3.232 4.658 6.033
% 5.384 , 13,2% 33,3% 60,0% 86,5% 100%
( / : 120 . 5.384 ) 15,86 . 39,96 . 72,0 . 103,8 . 120 .
16,0 55,8 . 127,8 . 231,6 . 351,2 .
/ 0 0 21,25 . 74,38 . 170 .
24
/ - 2016
26 2016, (...) - - . - - . , - ( -), - - 2010. ... - (), -
, - - HIV . - , - , - -. - , , . , , - , - , - -
:
...
2020
25
2020, - - . - 2013. - , 1.
, -, ..., . . 1, 1980-2011 -, ... -15 ( ). , . 2 - -15. . - , , -. , - , 1970, , - . , - - - , .
-, , - - 15 (. 3).
1 AIDS/HIV 2011-2013.
26
/ - 2016
- , , - , - , , . - , . , ,
- . , ... 2014 66% 55% -, - , -. - , , - , - . - , - -15 (. 4). , , HIV/AIDS. , HIV - - (. 5).
- ... () 1983, - . - - , , - . - - , . - , - - 1953, 1983, , -: - , , -, -. , , . -
27
- , -- (. 6), - - (. 7). , - , ... (. 8). , -, ... , - . 2009 2012, - , - 22%, - , 24%. - , . , - 20%. , - -: 4,0% 2009 7,8% 2013. 26% 2013 ( 8% 2000), - -15. , - - -
. - , , - -. , , - ( , 2009-2014) . , , , -, - . , - , - 2000, - -. , - - 15 (+ 67% + 80%, ), - - -15 (-59% -27%, ). - - 2020 .
: hamburger
28
/ - 2016
2020 - , - , , , , -, . - - , -- ( 1). 19 - - , : , Gini . - (- , , -), - . , -, - ... 2004 (-15). - , 61%
50 - - , - . , -
- 2020 - .
... : http://goo.gl/pXs4zU
2020
30
34I. . Mameletzis:
42. :
48: C
C
30 / - 2016
- - - C. , - ... , , , 20 2016,
- - C (Gilead, Bristol-Myers Squib, Abbvie, Janssen MSD). MSD - , -. , -
, C.
HEP C
31
: C
, - , 13 . , - 2012! , - - -, - 2016. , ... -. , . - , -, (Health Technology Assessment), . -. . -, -:
- - . - - , - - .
- - - , 13
32 / - 2016
C (HCV). , C - . - . 15% . - , -, , , . 80% .
10-20 , 10-30% 30 - . 2013 - -- ( ) . , -, 50%, - HCV, 1. , . , 40%
1, - 3, 15% 4 5% 2. 2014, - , - Gilead. - daclatasvir Bristol Myers Squibb, - - Abbvie, Janssen MSD. 100%!
(Budget Impact Analysis). -, - .
, - . - . - , - - . , - , - . , . , -
... , , - - , . - - - . 30.000 , 15.000, -, -. , , - 22.000 . , , - 1.400 . , , 160-170.000 - C. -, (80%) , . , . , , , - . .. , . , - , .
-
-
HE15013_21X28_HR.pdf 1 15/09/2015 9:50 ..
34 / - 2016
-, , - PhB, , - (...), H. . ..., , 69 , - . C - , - . - , - - . -
, - , - , , -. , , - , , , - . , -, C , - - . - C - .
... PhB - , Ioannis Hodges Mameletzis, - - HCV - .
:
:
...
35
: C
* HIV, ...
I. Hodges Mameletzis*
36 / - 2016
_ - ... - C ;
A_ , C, ... 90% 65%, 2030. , - (HBV) C (HCV). HCV -, -, .
_ ; , , ;
A_ - - , , . - -, -. , , . - HBV, , - - , ( ) - HBV HVC.
_ , ;
A_ - - ( ). , HBV HCV, . B - C - . - C 2030, 90% .
-
, -
-
37
: C
C, - 80% . -, - . , , 2030 ( ). 300 . , . - - C -, . - . - . , , , - . - HIV HCV - . - -. . , , - . , , ... .
_ - ;
A_ 2016, - 25 36. - . , , , , -, . , - . - ( ,
C) - . -, - , , , - .
_ - , ;
A_ - - . , - , . - HIV - . , , , . . - - HCV.
_ - - ;
A_ - ... - . , - , . - - . - - . . - , - . , , ,
,
38 / - 2016
- . - -, . . ; - ( )
, - ( , , , sex workers, -, - ). , . -, , , - , , -, , , - , , . , - , . - , . -, . , -
. . - - . C, - , . , , . -
, . - . . , . C HIV, . . . - -. - - , - . , -
C 2030,
90%
39
: C
C . , , - ( , , HCV, - ).
_ , - ;
A_ -
, . - HCV, , - -. - . , - HCV. , - . , - , . - ..., - .
_
, ;
A_ , - . , - - (European Center for Disease Control-ECDC), ... . , , .
, , . - . - . ... - . - , , . , - HIV - , - . , ...
- 194 , 28 2016, 69 - ..., - . 2030. - ... - , 65% - 80%, 7,1 - . - , - - - World Hepatitis Alliance, Raquel Peck. - , World Hepatitis Alliance 230 - -, (28/7), NOhep, 2030.
40 / - 2016
C
1945-1965;
1945 1965
5x C
3 4 ATOMA C
-, - C (HCV), 1989, 170 - , - 133 . , - C . :
(50-70% C 5 - ).
- ( ).
.
( 2-5%, - 30% HIV ).
- C. (1%).
piercing - ().
, , - ...
1992. , - .
, C - , - 1945-1965 - 5 , FDA .
, , , 1992 HCV.
I N F O G R A P H I C S
C
41
: C
, , . .
C
75%
C
1945-1965 (CDC)
HEP Cblood test
C
C
C o1
C
42 / - 2016
C - , PhB - , . , - , - , . - , , , - . , - - , , - .
, - . - C, - , - . , - - , . 28 , 194 - ..., - 2030.
C, , PhB .
:
:
*
43
: C
*
44 / - 2016
_ C ;
_ , 1,3%-1,6% , - 133.000 , - C. - C , - - . , C, , . - C , - . - -. , - , . , - - , , . -
, , , .
_ , , ;
_ C - . - 170 - C. , - , 133.000 - , - 20% -. , - - . , 3.700 - C, , , -, - . - . , C . - , , , -
C
45
: C
. , , - C - - . , - . , - - .
_ -, , ;
_ -, - - C . 1992, C, - (). -, - , - , - . -, C - 80%.
_ - C;
_ , - - C. , - - - -, - -.
- 2014, - , - - . 24 , - 100%, - C. - , .
_ C, , , - , -
46 / - 2016
. ;
_ - , - , - . - - - C ,
. , , C, , - , - . , - , , - - , - 50%. , -
C - . -, - . , - - .
_ - ;
_ - C - . , - - , - - .
_ - - , ;
47
: C
_ , - . - - , , C. - . - -, , , , , -.
_ - ; ;
_ - - . 28 2016, 194 - ... -, - 2030. 69 , -, - , - -, , - B C.
- B C 2030 - - -, 65% 80%, 7,1 - . - (...) 2030 -
. , - C - , - ( , , ), - , - , - - . , , - - .
48 / - 2016
C - . - , 130.000 C. - C -, -
, . C - , - - 1992, 40%
HCV .
,
-
,
C
49
: C
C (HCV) - - . HCV - . - HCV RNA 12 24 -, - (sustained virological response, SVR). HCV 1989 2011-2012, -- (IFN) 15- - (PEG-IFN), , (RBV), . PEG-IFN RBV 24-48 SVR 40-80% , - HCV. , PEG-IFN RBV -, , - . (2011-2014) , C - . - (boceprevir telaprevir: HCV) PEG-IFN RBV 1 - SVR 1, - , PEG-IFN RBV. , (2014-2015) - . 2014, () C. , -
50 / - 2016
HCV (sofosbuvir), (simeprevir), NS5A (daclatasvir), - sofosbuvir NS5A (ledipasvir) - , - (paritaprevir/ritonavir) - NS5A (ombitasvir) - (dasabuvir). , : (grazoprevir) NS5A - (elbasvir) sofosbuvir , NS5A (velpatasvir) .
. . , C , , - - sofosbuvir, - (- 95% , - 3 (- ) - SVR
51
: C
www.bms-greece.gr
52 / - 2016
2016, - (CHMP) - (EMA) - / - C. , - . -- -, - - (SOF) 400 mg - NS5A, (VEL) 100 mg. -/ Gilead Sciences 3:
ASTRAL-1, ASTRAL-2 ASTRAL-3, 1.035 - HCV 1-6, -
( Child-Pugh), 12 .
ASTRAL-4 267 HCV - 1-6 ( Child-Pugh), - 12 , -/ 24 .
- - 12 - (SVR12). CHMP - / . -, , 2014. , - /, , - 2014.
C
Sofosbuvir/Velpatasvir 52
Ombitasvir/Paritaprevir/Ritonavir + Dasabivir 54
Elbasvir/Grazoprevir 53
55
:
Sofosbuvir/Velpatasvir
53
: C
2016, - (CHMP) - (EMA) - /, - - - , 2.000 HCV, 20 , . , MSD ( Merck & Co) - SVR12 SVR24, , 12 24 - . -/ - 3:
C-EDGE Head-to-Head, - / Sofosbuvir Peginterferon/Ribavirin (pegIFN/RBV), HCV - 1 4 ,
- pegIFN/RBV.
C-EDGE IBLD, / HCV - 1, 4 6, - .
C-EDGE CO-STAR, - /- HCV 1, 4 6 .
, -/ - 28 - - , , C. H 2016, - 2016 , , 2017. /- - (FDA) 2016 - .
Elbasvir/Grazoprevir
54 / - 2016
2016, - (CHMP) - (EMA), - -//- - C 1b (GT1b) - ( Child-Pugh). CHMP -
3b TURQUOISE-III, - AbbVie C, 1. - - , 100% C 1b - ( Child-Pugh), - , 12 .
Ombitasvir/Paritaprevir/Ritonavir + Dasabivir
55
: C
, - () - -, - C, - - C1. - - - . - - - - C . , , -, . -
14 2016, - - C - , C - -. - - (PRAC), - (CHMP), . - - , - - . - , - - - - .
1 -: Daklinza (daclatasvir), Exviera (dasabuvir), Harvoni (sofosbuvir/ledipasvir), Olysio (simeprevir), Sovaldi (sofosbuvir) Viekirax (ombitasvir/paritaprevir/ritonavir).
56
/ - 2016
- , -, . - 49 , - E.coli, , - , -. - , , . -
, , . - -CDC ( ) - - , Reuters, Washington Post New York Times. , , 2015, - , , . - , . , . - - -
100 . .
CDC
49 E.coli,
57
58
/ - 2016
, , - CDC, , - . 49, 26 -, Antimicrobial Agents and Chemotherapy - . -E coli , mcr-1, - . - , - , - , - , - , . , - - 10 - , 100 . . - 2050, - - . - 40 . .
, , -, . 4,7 . . -. , , , -, . , - 1 . . - - , .
, - - David Cameron, - . , - - , - , - . , 2020 - . , . , - , - , -. : - , - ( 80), - - , - . , - ( 70% ) -
10 .
59
. , - - 2 . . ( -), , - - .. - -, - , .
, - , - . , , , - - . 14 . 12 17 -, . - . - -. . . - - , - . - , - . , -2 . - .
, , -, -, - . - - , - .
, - , . , , -, . James Tiedje, Michigan State University, - - - - . - - . - - . - , -, - , Tiedje. - - , - . , , - , .
, 100 . .
40 . . 10
60
/ -I 2016
- (..). , . ( 3()/. 18910, 390/21-3-2013), -, , - . -, .. . .
, . - , (), , , - . - .. - () . -
:
,
, . ,
Supply Chain and Logistics Manager([email protected]).
61
- - , , ... .., , .., - -. - .., - , -, , .. - - . , ( , - ..). .., - 536/2014 , - , . - .., - - . 80.000.000 , 300.000.000 - 1 . (!), -. , - .. . - , - ( ) .
62
/ -I 2016
,
,
- - (/) ( 3()/. 18910, 390/21-3-2013), - 146/03 (- ) (3) (, ) . , , - , . , , - - , / - , , , - , , - - . - - - .
/ - ,
- , . - . -, , , , . - , - (500) , - ( 1). -, , 15% - , - - , - /. - 5% , . - , - ( 2). , - , - - ( 3).
63
, - , ( 4).
- (4) - - (3) , 146/2003. - .. . , 1 - 3919 -
, 75.05.09 , 96.75.09 . 2 - 15-20% - 3913 -, 75.05.05 . , 96.75.05 - , . - - , - .. .
, -, :
96.75.05., ,
96.75.05.., - .
- 1 2 - , - - -. , 3 4 -
, . , - - , 73 , - -. -. - - 92.00. , . , - 96.73 , .
64
/ -I 2016
1/4/2015, - ( 7 . 3329/2005 81//2005). - , - ( 8 . 4308/2014, 1003/2014 . 8.1.1 & 8.9.1). , - .. (500 15%), - , - . , 500,00 , - () - ( 1). , .. 15-20% ( 2), . - - , - () , ( 4). , - , -, 5 241 .
.. - , . , -
- . - , -, (, - ) .
.. . :
, , . - .
( ) -, - . , . , , - .
- .
- . , - , , - , , ,
,
65
( - , ).
, - - . - - , , - , -
. , , , .. - - .
, - .. .
1.
30.00. 500 06.10.3919 500 90.07.75 500 75.05.09 500 06.21.3919 500 96.75.09 500 1.
38.03. 500 06.21.3919 500 _ _ _ 30.00. 500 06.31.3919 500 2. 15-20% / ( 5.000 )
30.00. 5.000 06.10.3913 5.000 90.07.75 5.000 75.05.05 5.000 06.21.3913 5.000 96.75. 5.000 2.
38.03. 5.000 06.21.3913 5.000 _ _ _ 30.00. 5.000 06.31.3913 5.000
3.
( . 2.500 )
_ _ _ _ _ _ 92.00. 2.500 92.00.09. 2.500 .99
4. ( 3.000 )
30.00. 3.000 06.10.3149 3.000 90.07.73 3.000 73.05. 3.000 06.21.3149 3.000 96.73. 3.000 4.
38.03. 3.000 06.21.3149 3.000 _ _ _ 30.00. 3.000 06.31.3149 3.000
A
86 / 2011
courier
cargo
logistics
!
C.C.L. :
100, 151 25 ,: 210 8056550, FAX: 210 8056553www.tachydema.gr
:E.E.T.T. A.M.: 03-017
, ...
1
(, , , ...)
86-87.indd 86 22/12/2011 5:28:03
87
courier
cargo
logistics
!
C.C.L. :
100, 151 25 ,: 210 8056550, FAX: 210 8056553www.tachydema.gr
:E.E.T.T. A.M.: 03-017
, ...
1
(, , , ...)
86-87.indd 87 22/12/2011 5:28:03
68
/ - 2016
- , - , , , - - Reputation Institute, - , 14 . , - 23.000 15 , - -. 7 :
1) , 2) , 3) , 4) , 5) , 6) 7) .
, - , - - Bayer, 4 7 -. - Abbott Laboratories, Novo Nordisk ,
Bayer
Reputation Institute
69
70
/ - 2016
Roche Merck & Co . , , - , 2015. , , - . Bayer Novo Nordisk 7 , - - , Reputation Institute.
- -, , , , , - . -, , , - - Kasper Ulf Nielsen, executive partner Reputation Institute, -: ,
- - . 18-24 , - .
Bayer, Abbott
Novo Nordisk
Reputation Institute
1. Bayer/ 70,6
2. Abbott Laboratories 68,7
3. Novo Nordisk 68.5
4. Roche 68.4
5. Merck & Co 68,3
6. Sanofi 67.8
7. Allergan 67,5
8. AstraZeneca 67,1
9. Eli Lilly 67,1
10. Abbvie 67.0
11. GlaxoSmithKline 66,9
12. Novartis 66,7
13. Bristol-Myers Squibb 66,0
14. Pfizer 65,9.
... , .
PhB . , , .
, , . .
, . ... .
, .
V I R U S
72 / -Io 2016
!
4 .
-. PhB -, . , , -
, . - - - ..., - . : - .
, - - . , , , - , .
M , , , , 4 . . - . 2% , - . , - . , .
73
social media!
M - - Facebook Twitter , . , , PhB -- - ,
-. , -, Facebook, - like - . , social media. ,
, . , - . PhB - . PhB - - . , , . - .
In Brief -! - - . - - - , , -. , , - , -. , , - 30%, 80%.
V I R U S
74 / -Io 2016
. -
. PhB. - 40 , . . . 4 . , - . - . , . , , . . , , - PhB.
In Brief
! - - , - , -. , - , - - , . - . , , .
A - . , - , PhB
- , . , , . , - -
, . , - - - , .
75
76
A
/ -Io 2016
Baxter International -
, - - . 1931 -. - 30 - 120 .
2016 ( ), - 2,37 . . - 3,38 . . (- ).
[BloomBerg TIcker: BAX:US ] [reUTerS TIcker: BAX:N]
BAXTER INTERNATIONAL INC. ,
:
, , . , VRS VRS . , , .
VALUATION & RESEARCH SPECIALISTS (VRS) - www.vrs.gr 104, 10564 . 210 3219557, 698 3603160 Email: [email protected]
& . : 2 0 0 2
52 ( )
P/E
(x)
30
25
20
15
10
5
0 2015 P/E P/E 2016 S&P P/E 2016 STOXX 600 P/E 2016
: FACTSET, VRS.24,8
15,917,6
15,9
50
45
40
35
30
252/6/2015 11/8/2015 20/10/2015 29/12/2015 8/3/2016 17/5/2016
:
3 2016
( . )
$43,48
. ( .) 552,26
. ( . $) 24.012,40
. . (52 .)
8.401.096
Beta 0,80
. 52 . ($) 46,25 USD
. 52 . ($) 31,98 USD
. 1- -1,75%
. 6- 17,57%
. 12- 24,60%
: ,
77
, , . , VRS VRS . , , .
VRS SFiT 104, 10564 . 210 3316358, 6945 851420 Email: [email protected]
V R S - S F i T: . : 2 0 0 2
& 2009-2015 (, . . ) EBITDA P/ P/BV EV / / ROE (x) (x) EBITDA % (x) (x)
2010 12.843 2.647 1.890 1.427 16,8 3,7 10,5 0,67 22%2011 13.893 3.575 2.809 2.256 10,6 3,5 7,8 0,73 33%2012 14.190 3.799 2.889 2.326 10,3 3,4 6,7 0,69 33%2013 9.413 3.313 2.550 2.012 11,9 2,8 8,3 0,72 24%2014 10.719 3.989 3.052 2.497 9,6 3,0 7,4 1,02 31%2015 9.968 2.135 1.180 968 24,8 2,7 12,9 0,65 11%
: / . : (3 2016), 2016.
2010-2015 (, . . ) . . 2010 2011 2012 2013 2014 2015
12.843 13.893 14.190 9.413 10.719 9.968 ( .) 6.885 6.847 6.889 5.251 6.138 5.822 % 46,39% 50,72% 51,45% 44,22% 42,74% 41,59% 1.427 2.256 2.326 2.012 2.497 968 % 11,1% 16,2% 16,4% 21,4% 23,3% 9,7% 2.685 2.905 3.270 2.733 2.925 2.213 126 140 149 243 94 101 2.371 2.628 2.803 3.499 1.577 1.604 64 64 62 113 64 63 2.265 2.420 2.425 2.911 1.884 1.731 234 235 260 338 159 167 4.411 4.409 4.899 4.866 2.677 2.666 Operating Cycle 190 204 211 356 158 164Cash Cycle ( ) -44 -31 -49 18 -1 -3
: / . : (3 2016), 2016.
.
.
S&P 500 5
( = 100): ,
180
160
140
120
100
80
60
4022/6/2011 22/6/2012 22/6/2013 22/6/2014 22/6/2015
S&P 500 METOXH
78 / -I 2016
!
;
-: -, -, . , - -. , , . -, - , . -
, , , - . -, , , - . , - . , , placebo ( ) ( - ). - .
- - . , . , -, , . , -
, , - , , . , - , -, , - , - . , - 20.000 - 13 , 70% - .
, ! - - . 5.000 , , - - , -
! , 30 -, - . , , 20 - 36% 30 .
79
: botox
;
;
- . : - . :
- 50% , - .
botox , - 3.500 , - - , .
New England Research Institute -
45%, 50%.
, - . - , - .
-. , - . , , - , - , , . , , , , - , , . , 25-55 . , 20%, . 31%, , , -, .
- , , - , . -, PLOS ONE, - -, - . -, 0,8 -
. O - . 80 -, 8 , : 0,8 . x 72 = 57,6 - . , - 10 . , - 15 . .
80 / - 2016
! Ph.B (Pharma & Health Business)!
( )
&
: 50 : 30
: 0 : 90
( )
: 10
( ..)
: (089/470271-92 / IBAN GR46 0110 0890 0000 0894 7027 192)
ETHOS MEDIA .. . fax 210 998 4953, . .
-
*
*
..
.
E-MAIL .
FAX * *
*
: , 210 998 4909, [email protected] : ETHOS MEDA S.A., 29, 174 56 , Fax: 210 998 4953
!
80 / - 2016
! Ph.B (Pharma & Health Business)!
( )
&
: 50 : 30
: 70 : 90
( )
: 10
( ..)
: (089/470271-92 / IBAN GR46 0110 0890 0000 0894 7027 192)
ETHOS MEDIA .. . fax 210 998 4953, . .
-
*
*
..
.
E-MAIL .
FAX * *
*
: , 210 998 4909, [email protected] : ETHOS MEDIA S.A., 29, 174 56 , Fax: 210 998 4953
Ph.B , , e-mail!
, . e-book , rich media (video, , flash animations),
hyperlinks, , ...!
!
80.indd 80 26/2/2016 3:12:11
PFI
-02-
FEB
16
Pfizer, - , 1849 .
, .
C
M
Y
CM
MY
CY
CMY
K
AbbVie_bestworkplaces2016TEL2_21x28.pdf 1 4/7/16 2:00 PM
GR1603458162
final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1 18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..
#035 -2 0 1 6
www . v i r u s . c o m . g rI S S N : 2 2 4 1 - 0 9 6 1
pi
pi
4 Clinical Research ConferenceThink Tank
001 EX.indd 1 3/3/2016 7:50:57 pi
/ #0
35
/
-
2
01
6ISSN
: 224
1-09
61
00 ANAPTYGMA EXOFYLOU.indd 1 3/3/2016 7:51:39 pi
/ #03
7 /
-
2016
final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1final_KTX SfEE_2015_21x28cm.indd 1 18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..18/12/15 4:27 ..
#035 -2 0 1 6
www . v i r u s . c o m . g rI S S N : 2 2 4 1 - 0 9 6 1
pi
pi
4 Clinical Research ConferenceThink Tank
001 EX.indd 1 3/3/2016 7:50:57 pi
/ #0
35
/
-
2
01
6ISSN
: 224
1-09
61
00 ANAPTYGMA EXOFYLOU.indd 1 3/3/2016 7:51:39 pi
#037- 2 0 1 6
Jean-Michel Malbrancq
C